Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1926 1
1929 1
1930 3
1932 1
1938 1
1947 2
1948 2
1949 1
1950 2
1951 1
1952 2
1954 3
1955 2
1956 2
1957 3
1958 1
1959 2
1960 1
1961 3
1962 2
1963 4
1964 3
1965 3
1966 9
1967 4
1968 4
1969 4
1970 10
1971 13
1972 6
1973 7
1974 8
1975 11
1976 5
1977 10
1978 10
1979 15
1980 17
1981 16
1982 36
1983 20
1984 32
1985 34
1986 44
1987 46
1988 49
1989 41
1990 54
1991 45
1992 57
1993 58
1994 60
1995 33
1996 44
1997 53
1998 48
1999 58
2000 59
2001 54
2002 66
2003 76
2004 83
2005 80
2006 88
2007 97
2008 88
2009 110
2010 133
2011 139
2012 144
2013 130
2014 150
2015 133
2016 131
2017 170
2018 143
2019 138
2020 199
2021 231
2022 165
2023 148
2024 133
2025 138
2026 73

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,917 results

Results by year

Filters applied: . Clear all
Page 1
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.
Shen L, Kato K, Kim SB, Ajani JA, Zhao K, He Z, Yu X, Shu Y, Luo Q, Wang J, Chen Z, Niu Z, Zhang L, Yi T, Sun JM, Chen J, Yu G, Lin CY, Hara H, Bi Q, Satoh T, Pazo-Cid R, Arkenau HT, Borg C, Lordick F, Li L, Ding N, Tao A, Shi J, Van Cutsem E; RATIONALE-302 Investigators. Shen L, et al. Among authors: hara h. J Clin Oncol. 2022 Sep 10;40(26):3065-3076. doi: 10.1200/JCO.21.01926. Epub 2022 Apr 20. J Clin Oncol. 2022. PMID: 35442766 Free PMC article. Clinical Trial.
Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial.
Kato K, Machida R, Ito Y, Daiko H, Ozawa S, Ogata T, Hara H, Kojima T, Abe T, Bamba T, Watanabe M, Kawakubo H, Shibuya Y, Tsubosa Y, Takegawa N, Kajiwara T, Baba H, Ueno M, Takeuchi H, Nakamura K, Kitagawa Y; JCOG1109 investigators. Kato K, et al. Among authors: hara h. Lancet. 2024 Jul 6;404(10447):55-66. doi: 10.1016/S0140-6736(24)00745-1. Epub 2024 Jun 11. Lancet. 2024. PMID: 38876133 Clinical Trial.
Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023.
Kitagawa Y, Matsuda S, Gotoda T, Kato K, Wijnhoven B, Lordick F, Bhandari P, Kawakubo H, Kodera Y, Terashima M, Muro K, Takeuchi H, Mansfield PF, Kurokawa Y, So J, Mönig SP, Shitara K, Rha SY, Janjigian Y, Takahari D, Chau I, Sharma P, Ji J, de Manzoni G, Nilsson M, Kassab P, Hofstetter WL, Smyth EC, Lorenzen S, Doki Y, Law S, Oh DY, Ho KY, Koike T, Shen L, van Hillegersberg R, Kawakami H, Xu RH, Wainberg Z, Yahagi N, Lee YY, Singh R, Ryu MH, Ishihara R, Xiao Z, Kusano C, Grabsch HI, Hara H, Mukaisho KI, Makino T, Kanda M, Booka E, Suzuki S, Hatta W, Kato M, Maekawa A, Kawazoe A, Yamamoto S, Nakayama I, Narita Y, Yang HK, Yoshida M, Sano T. Kitagawa Y, et al. Among authors: hara h. Gastric Cancer. 2024 May;27(3):401-425. doi: 10.1007/s10120-023-01457-3. Epub 2024 Feb 22. Gastric Cancer. 2024. PMID: 38386238 Free PMC article. No abstract available.
Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164.
Le DT, Diaz LA Jr, Kim TW, Van Cutsem E, Geva R, Jäger D, Hara H, Burge M, O'Neil BH, Kavan P, Yoshino T, Guimbaud R, Taniguchi H, Élez E, Al-Batran SE, Boland PM, Cui Y, Leconte P, Marinello P, André T. Le DT, et al. Among authors: hara h. Eur J Cancer. 2023 Jun;186:185-195. doi: 10.1016/j.ejca.2023.02.016. Epub 2023 Feb 24. Eur J Cancer. 2023. PMID: 37141828
Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer.
Kawakami H, Kadowaki S, Makiyama A, Tsuda M, Hirata K, Sugimoto N, Machida N, Hara H, Hirano H, Esaki T, Komatsu Y, Hironaka S, Kobayashi Y, Kakimi K, Chiba Y, Boku N, Hyodo I, Muro K. Kawakami H, et al. Among authors: hara h. J Clin Oncol. 2025 Jul;43(19):2184-2195. doi: 10.1200/JCO-24-02463. Epub 2025 May 16. J Clin Oncol. 2025. PMID: 40378356 Clinical Trial.
ONO-4578 Plus Nivolumab in Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer.
Kawazoe A, Yamaguchi K, Hamaguchi T, Narita Y, Boku S, Oshima T, Hara H, Hamamoto Y, Ishido K, Esaki T, Hosaka H, Yasui H, Koeda K, Nishina T, Tsuji Y, Fukagawa T, Goto M, Oki E, Sugimoto N, Matsuoka H, Yokoyama F, Yoshida T, Yoshida K, Oshima Y, Iwasa S. Kawazoe A, et al. Among authors: hara h. Cancer Sci. 2025 Sep;116(9):2523-2536. doi: 10.1111/cas.70130. Epub 2025 Jul 6. Cancer Sci. 2025. PMID: 40618725 Free PMC article. Clinical Trial.
Sex Differences in Frequency, Severity, and Distribution of Cerebral Microbleeds.
Fandler-Höfler S, Eppinger S, Ambler G, Nash P, Kneihsl M, Lee KJ, Lim JS, Shiozawa M, Koga M, Li L, Lovelock C, Chabriat H, Hennerici M, Wong YK, Mak HKF, Prats-Sanchez L, Martínez-Domeño A, Inamura S, Yoshifuji K, Arsava EM, Horstmann S, Purrucker J, Lam BYK, Wong A, Kim YD, Song TJ, Lemmens R, Uysal E, Tanriverdi Z, Bornstein NM, Ben Assayag E, Hallevi H, Molad J, Nishihara M, Tanaka J, Coutts SB, Polymeris A, Wagner B, Seiffge DJ, Lyrer P, Kappelle LJ, Al-Shahi Salman R, Hernandez MV, Jäger HR, Lip GYH, Fischer U, El-Koussy M, Mas JL, Legrand L, Karayiannis C, Phan T, Gunkel S, Christ N, Abrigo J, Chu W, Leung T, Chappell F, Makin S, Hayden D, Williams DJ, Mess WH, Kooi ME, Barbato C, Browning S, Tuladhar AM, Maaijwee N, Guevarra AC, Mendyk AM, Delmaire C, Köhler S, van Oostenbrugge R, Zhou Y, Xu C, Hilal S, Robert C, Chen C, Lou M, Staals J, Bordet R, Kandiah N, de Leeuw FE, Simister R, Bos D, Kelly PJ, Wardlaw J, Soo Y, Fluri F, Srikanth V, Calvet D, Jung S, Kwa VIH, Engelter ST, Peters N, Smith EE, Hara H, Yakushiji Y, Orken DN, Thijs V, Heo JH, Mok V, Veltkamp R, Ay H, Imaizumi T, Lau KK, Jouvent E, Rothwell PM, Toyoda K, Bae HJ, Marti-Fabregas J, Wilson D, Best J, … See abstract for full author list ➔ Fandler-Höfler S, et al. Among authors: hara h. JAMA Netw Open. 2024 Oct 1;7(10):e2439571. doi: 10.1001/jamanetworkopen.2024.39571. JAMA Netw Open. 2024. PMID: 39405058 Free PMC article.
NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial.
Lu Z, Du W, Jiao X, Wang Y, Shi J, Shi Y, Shu Y, Niu Z, Hara H, Wu J, Hsu CH, Van Cutsem E, Brock MV, Zhang Z, Ding N, Zhang Y, Shen Z, Shen L. Lu Z, et al. Among authors: hara h. J Clin Oncol. 2025 Jun;43(16):1898-1909. doi: 10.1200/JCO-24-01818. Epub 2025 Apr 3. J Clin Oncol. 2025. PMID: 40179324 Free PMC article. Clinical Trial.
Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study.
Metges JP, Kato K, Sun JM, Shen L, Enzinger PC, Adenis A, Doi T, Kojima T, Li Z, Kim SB, Cho BC, Mansoor W, Li SH, Sunpaweravong P, Alsina M, Buchschacher GL Jr, Hara H, Tsuji A, Wu J, Shah S, Bhagia P, Shah MA. Metges JP, et al. Among authors: hara h. ESMO Open. 2025 Dec;10(12):105854. doi: 10.1016/j.esmoop.2025.105854. Epub 2025 Nov 18. ESMO Open. 2025. PMID: 41259897 Free PMC article. Clinical Trial.
3,917 results